Research ExplorerPublicationsOral delta 9-tetrahydrocannabinol improved refractory Gilles...

Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

Standard

Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. / Hasan, Alkomiet; Rothenberger, Aribert; Münchau, Alexander; Wobrock, Thomas; Falkai, Peter; Roessner, Veit.

In: J CLIN PSYCHOPHARM, Vol. 30, No. 2, 2, 2010, p. 190-192.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hasan, A, Rothenberger, A, Münchau, A, Wobrock, T, Falkai, P & Roessner, V 2010, 'Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.', J CLIN PSYCHOPHARM, vol. 30, no. 2, 2, pp. 190-192. <http://www.ncbi.nlm.nih.gov/pubmed/20520294?dopt=Citation>

APA

Hasan, A., Rothenberger, A., Münchau, A., Wobrock, T., Falkai, P., & Roessner, V. (2010). Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J CLIN PSYCHOPHARM, 30(2), 190-192. [2]. http://www.ncbi.nlm.nih.gov/pubmed/20520294?dopt=Citation

Vancouver

Hasan A, Rothenberger A, Münchau A, Wobrock T, Falkai P, Roessner V. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J CLIN PSYCHOPHARM. 2010;30(2):190-192. 2.

Bibtex

@article{4d0878133274423abc01ef3059582ec7,
title = "Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.",
abstract = "To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation.",
keywords = "Humans, Male, Adolescent, dosage, Neural Inhibition drug effects, Administration, Oral, Transcranial Magnetic Stimulation methods, Cerebral Cortex drug effects, Tetrahydrocannabinol administration, Tourette Syndrome blood, Humans, Male, Adolescent, dosage, Neural Inhibition drug effects, Administration, Oral, Transcranial Magnetic Stimulation methods, Cerebral Cortex drug effects, Tetrahydrocannabinol administration, Tourette Syndrome blood",
author = "Alkomiet Hasan and Aribert Rothenberger and Alexander M{\"u}nchau and Thomas Wobrock and Peter Falkai and Veit Roessner",
year = "2010",
language = "Deutsch",
volume = "30",
pages = "190--192",
journal = "J CLIN PSYCHOPHARM",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report.

AU - Hasan, Alkomiet

AU - Rothenberger, Aribert

AU - Münchau, Alexander

AU - Wobrock, Thomas

AU - Falkai, Peter

AU - Roessner, Veit

PY - 2010

Y1 - 2010

N2 - To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation.

AB - To describe the clinical course of the Delta 9-tetrahydrocannabinol (Delta 9-THC) treatment of a boy with Gilles de la Tourette Syndrome (TS) and comorbid attention-deficit/hyperactivity disorder (ADHD) in relation to Delta 9-THC plasma levels and intracortical inhibition measured by transcranial magnetic stimulation.

KW - Humans

KW - Male

KW - Adolescent

KW - dosage

KW - Neural Inhibition drug effects

KW - Administration, Oral

KW - Transcranial Magnetic Stimulation methods

KW - Cerebral Cortex drug effects

KW - Tetrahydrocannabinol administration

KW - Tourette Syndrome blood

KW - Humans

KW - Male

KW - Adolescent

KW - dosage

KW - Neural Inhibition drug effects

KW - Administration, Oral

KW - Transcranial Magnetic Stimulation methods

KW - Cerebral Cortex drug effects

KW - Tetrahydrocannabinol administration

KW - Tourette Syndrome blood

M3 - SCORING: Zeitschriftenaufsatz

VL - 30

SP - 190

EP - 192

JO - J CLIN PSYCHOPHARM

JF - J CLIN PSYCHOPHARM

SN - 0271-0749

IS - 2

M1 - 2

ER -